AIDS vaccines and preexposure prophylaxis: is synergy possible?
暂无分享,去创建一个
A. Kamali | W. Koff | A. McDermott | O. Anzala | J. Excler | P. Fast | F. Priddy | J. Gilmour | E. Sanders | W. Rida | S. Berkley | G. Mutua
[1] R. Berger. Re.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. , 2011, The Journal of urology.
[2] J. Kimani,et al. Cohorts for the study of HIV‐1-exposed but uninfected individuals: benefits and limitations. , 2010, The Journal of infectious diseases.
[3] S. Blower,et al. Costs of eliminating HIV in South Africa have been underestimated , 2010, The Lancet.
[4] Lynn Morris,et al. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.
[5] J. Benito,et al. Low-Level Exposure to HIV Induces Virus-Specific T Cell Responses and Immune Activation in Exposed HIV-Seronegative Individuals , 2010, The Journal of Immunology.
[6] R. Kaul,et al. HIV viral set point and host immune control in individuals with HIV-specific CD8+ T-cell responses prior to HIV acquisition , 2010, AIDS.
[7] Phalguni Gupta,et al. Genetic characterization of HIV-1 from semen and blood from clade C-infected subjects from India and effect of therapy in these body compartments. , 2010, Virology.
[8] Nancy S. Padian,et al. Behavior Change Interventions to Prevent HIV Infection among Women Living in Low and Middle Income Countries: A Systematic Review , 2010, AIDS and Behavior.
[9] G. Shaw,et al. A Limited Number of Simian Immunodeficiency Virus (SIV) env Variants Are Transmitted to Rhesus Macaques Vaginally Inoculated with SIVmac251 , 2010, Journal of Virology.
[10] Peter B Gilbert,et al. Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts , 2010, Statistics in medicine.
[11] Sandra I McCoy,et al. Weighing the gold in the gold standard: challenges in HIV prevention research , 2010, AIDS.
[12] Ashley T. Haase,et al. Targeting early infection to prevent HIV-1 mucosal transmission , 2010, Nature.
[13] W. Koff. Accelerating HIV vaccine development , 2010, Nature.
[14] W. Heneine,et al. Oral pre-exposure prophylaxis for HIV prevention. , 2010, Trends in pharmacological sciences.
[15] C. Dye,et al. Highly active antiretroviral treatment for the prevention of HIV transmission , 2010, Journal of the International AIDS Society.
[16] J. McIntyre. Use of antiretrovirals during pregnancy and breastfeeding in low-income and middle-income countries , 2010, Current opinion in HIV and AIDS.
[17] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[18] R. Kaul,et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy , 2009, AIDS.
[19] S. Butera,et al. Repeated rectal SHIVSF162P3 exposures do not consistently induce sustained T cell responses prior to systemic infection in the repeat-low dose preclinical macaque model. , 2009, AIDS research and human retroviruses.
[20] M. Ardo,et al. A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure , 2009 .
[21] C. Pasquier,et al. Determining Seminal Plasma Human Immunodeficiency Virus Type 1 Load in the Context of Efficient Highly Active Antiretroviral Therapy , 2009, Journal of Clinical Microbiology.
[22] Matthias Egger,et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis , 2009, AIDS.
[23] A. Fauci,et al. Universal voluntary testing and treatment for prevention of HIV transmission. , 2009, JAMA.
[24] J. Brenchley,et al. Initiation of Antiretroviral Therapy 48 Hours after Infection with Simian Immunodeficiency Virus Potently Suppresses Acute-Phase Viremia and Blocks the Massive Loss of Memory CD4+ T Cells but Fails To Prevent Disease , 2009, Journal of Virology.
[25] Alan S. Perelson,et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1 , 2009, The Journal of experimental medicine.
[26] R. Fontana. Side effects of long‐term oral antiviral therapy for hepatitis B , 2009, Hepatology.
[27] A. Kamali,et al. CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa , 2009, PloS one.
[28] K. S. Kim,et al. Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques. , 2009, Virology.
[29] R. Detels. The 'immunologic advantage' of HIV-exposed seronegative individuals , 2009 .
[30] Ying-Ru Lo,et al. Can antiretroviral therapy eliminate HIV transmission? , 2009, The Lancet.
[31] Christopher Dye,et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model , 2009, The Lancet.
[32] Devan V Mehrotra,et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.
[33] H. Furrer,et al. Tenofovir use is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study , 2008, Antiviral therapy.
[34] D. Barouch,et al. Challenges in the development of an HIV-1 vaccine , 2008, Nature.
[35] M. Carrington,et al. Drug-Susceptible HIV-1 Infection Despite Intermittent Fixed-Dose Combination Tenofovir/Emtricitabine as Prophylaxis Is Associated With Low-Level Viremia, Delayed Seroconversion, and an Attenuated Clinical Course , 2008, Journal of acquired immune deficiency syndromes.
[36] J. Heeney,et al. Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel , 2008, PLoS medicine.
[37] A. Levy,et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. , 2008, The Journal of infectious diseases.
[38] John P. Moore,et al. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans , 2008, Nature Medicine.
[39] Dennis R. Burton,et al. Toward an AIDS Vaccine , 2008, Science.
[40] J. Dik F. Habbema,et al. The Impact of Pre-Exposure Prophylaxis (PrEP) on HIV Epidemics in Africa and India: A Simulation Study , 2008, PloS one.
[41] W. Heneine,et al. Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques. , 2008, AIDS research and human retroviruses.
[42] Myron S. Cohen,et al. The Pharmacokinetics and Viral Activity of Tenofovir in the Male Genital Tract , 2008, Journal of acquired immune deficiency syndromes.
[43] Michael Monsour,et al. Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir , 2008, PLoS medicine.
[44] D. Montefiori,et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope , 2008, AIDS.
[45] D. Venzon,et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). , 2007, Vaccine.
[46] W. Koff,et al. A strategy for accelerating the development of preventive AIDS vaccines. , 2007, AIDS.
[47] A. Grulich,et al. The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV , 2007, HIV medicine.
[48] Christopher D Pilcher,et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection , 2007, AIDS.
[49] N. Suksomboon,et al. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother‐to‐child transmission of HIV infection , 2007, Journal of clinical pharmacy and therapeutics.
[50] E. Rosenberg,et al. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. , 2007, The Journal of infectious diseases.
[51] M. Roland. Postexposure prophylaxis after sexual exposure to HIV , 2007, Current opinion in infectious diseases.
[52] S. Blower,et al. Narrative Review: Antiretroviral Therapy to Prevent the Sexual Transmission of HIV-1 , 2007, Annals of Internal Medicine.
[53] J. Margolick,et al. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. , 2007, The Journal of infectious diseases.
[54] D. Nixon,et al. Strong HIV-1-Specific T Cell Responses in HIV-1-Exposed Uninfected Infants and Neonates Revealed after Regulatory T Cell Removal , 2006, PloS one.
[55] M. Hudgens,et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. , 2006, The Journal of infectious diseases.
[56] D. Mehrotra,et al. A Comparison of Eight Methods for the Dual‐Endpoint Evaluation of Efficacy in a Proof‐of‐Concept HIV Vaccine Trial , 2006, Biometrics.
[57] Evan Wood,et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic , 2006, The Lancet.
[58] Jiang Fan,et al. Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239 , 2006, Journal of Virology.
[59] A. Haase. Perils at mucosal front lines for HIV and SIV and their hosts , 2005, Nature Reviews Immunology.
[60] B. Kearney,et al. Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside Regimens , 2005, Journal of acquired immune deficiency syndromes.
[61] Eun-Young Kim,et al. Propagation and Dissemination of Infection after Vaginal Transmission of Simian Immunodeficiency Virus , 2005, Journal of Virology.
[62] B. Clotet,et al. Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients , 2005, Antimicrobial Agents and Chemotherapy.
[63] O. Laeyendecker,et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.
[64] Bikram Chakraborty,et al. Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation , 2005, Journal of Clinical Microbiology.
[65] F. Rousseau,et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. , 2004, AIDS research and human retroviruses.
[66] R. Singh,et al. The Clinical Benefits of Tenofovir for Simian Immunodeficiency Virus–Infected Macaques Are Larger Than Predicted by its Effects on Standard Viral and Immunologic Parameters , 2004, Journal of acquired immune deficiency syndromes.
[67] R. Singh,et al. CD8+-Cell-Mediated Suppression of Virulent Simian Immunodeficiency Virus during Tenofovir Treatment , 2004, Journal of Virology.
[68] D. Watkins,et al. Repeated Low-Dose Mucosal Simian Immunodeficiency Virus SIVmac239 Challenge Results in the Same Viral and Immunological Kinetics as High-Dose Challenge: a Model for the Evaluation of Vaccine Efficacy in Nonhuman Primates , 2004, Journal of Virology.
[69] Y. Endo,et al. Early Control of Highly Pathogenic Simian Immunodeficiency Virus/Human Immunodeficiency Virus Chimeric Virus Infections in Rhesus Monkeys Usually Results in Long-Lasting Asymptomatic Clinical Outcomes , 2003, Journal of Virology.
[70] Ronald H Gray,et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda , 2003, AIDS.
[71] J. Blanchard,et al. Transient early post‐inoculation anti‐retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut‐associated lymphoid tissues in SIVmac239‐infected rhesus macaques, but not resistance to rechallenge , 2003, Journal of medical primatology.
[72] P. Reichelderfer,et al. Recent observations on HIV type-1 infection in the genital tract of men and women. , 2003, AIDS.
[73] R. Schooley,et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study , 2002, AIDS.
[74] V. Robison,et al. Male Viral Load and Heterosexual Transmission of HIV‐1 Subtype E in Northern Thailand , 2002, Journal of acquired immune deficiency syndromes.
[75] B. M. Flynn,et al. Role of CD8+ Lymphocytes in Control of Simian Immunodeficiency Virus Infection and Resistance to Rechallenge after Transient Early Antiretroviral Treatment , 2001, Journal of Virology.
[76] J. Kahn,et al. Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults , 2001, Antimicrobial Agents and Chemotherapy.
[77] K. V. Van Rompay,et al. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. , 2001, The Journal of infectious diseases.
[78] S. Vermund,et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. , 2001, AIDS research and human retroviruses.
[79] P. Sen,et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model , 2001, AIDS.
[80] T. Lehner,et al. Mucosal exposure to subinfectious doses of SIV primes gut-associated antibody-secreting cells and T cells: lack of enhancement by nonneutralizing antibody. , 2001, Virology.
[81] P. Rácz,et al. Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment. , 2001, Virology.
[82] J. Lifson,et al. Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA. , 2001, Virology.
[83] M. Nowak,et al. Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus. , 2000, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[84] Joseph C. Sun,et al. Post‐exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection , 2000, Journal of medical primatology.
[85] K. Überla,et al. Suppression of Acute Viremia by Short-Term Postexposure Prophylaxis of Simian/Human Immunodeficiency Virus SHIV-RT-Infected Monkeys with a Novel Reverse Transcriptase Inhibitor (GW420867) Allows for Development of Potent Antiviral Immune Responses Resulting in Efficient Containment of Infection , 2000, Journal of Virology.
[86] T. Quinn,et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.
[87] B. M. Flynn,et al. Containment of Simian Immunodeficiency Virus Infection: Cellular Immune Responses and Protection from Rechallenge following Transient Postinoculation Antiretroviral Treatment , 2000, Journal of Virology.
[88] K. Überla,et al. Antiretroviral Therapy during Primary Immunodeficiency Virus Infection Can Induce Persistent Suppression of Virus Load and Protection from Heterologous Challenge in Rhesus Macaques , 2000, Journal of Virology.
[89] R. Kaul,et al. HIV-1-Specific Mucosal CD8+ Lymphocyte Responses in the Cervix of HIV-1-Resistant Prostitutes in Nairobi1 , 2000, The Journal of Immunology.
[90] N. Pedersen,et al. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Therapy Prolongs Survival of Infant Macaques Inoculated with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA , 1999, Antimicrobial Agents and Chemotherapy.
[91] N. Pedersen,et al. Early Short-Term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine Treatment Favorably Alters the Subsequent Disease Course in Simian Immunodeficiency Virus-Infected Newborn Rhesus Macaques , 1999, Journal of Virology.
[92] S. Rowland-Jones,et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. , 1998, The Journal of clinical investigation.
[93] D. Cardo,et al. A Case-Control Study of HIV Seroconversion in Health Care Workers After Percutaneous Exposure , 1998 .
[94] N. Pedersen,et al. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. , 1998, AIDS research and human retroviruses.
[95] J. Lifson,et al. Effectiveness of Postinoculation (R)-9-(2-Phosphonylmethoxypropyl)Adenine Treatment for Prevention of Persistent Simian Immunodeficiency Virus SIVmne Infection Depends Critically on Timing of Initiation and Duration of Treatment , 1998, Journal of Virology.
[96] B. Robbins,et al. Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA , 1998, Antimicrobial Agents and Chemotherapy.
[97] D. Cardo,et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. , 1997, The New England journal of medicine.
[98] R. Royce,et al. Sexual transmission of HIV. , 1997, The New England journal of medicine.
[99] R. Grant,et al. Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine , 1995, Science.
[100] D. Lawrence,et al. Some statistical issues in HIV vaccine trials. , 1994, Statistics in medicine.
[101] W. Willett,et al. The 2 × 2 factorial design: Its application to a randomized trial of aspirin and U.S. physicians , 1985 .
[102] S. Karim,et al. Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges , 2009 .
[103] C R Weinberg,et al. Less is more, except when less is less: Studying joint effects. , 2009, Genomics.
[104] R. Detels. The 'immunologic advantage' of HIV-exposed seronegative individuals. , 2009, AIDS.
[105] M. Robb,et al. This is an open-access article distributed under the terms... , 2008 .
[106] W. Willett,et al. The 2 x 2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians. , 1985, Statistics in medicine.